États-Unis · Agences & temps réel · PR Newswire

Rakuten Medical Presents Long-Term Follow-up Results of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for R/M HNSCC at ESMO 2026

Publié par PR Newswire · États-Unis il y a 1 h

Median DOR of 44.3 months supports durability of response 4-year overall survival rate of 35.3% and median OS of 28.2 months suggest meaningful long-term survival Long-term…

Lire l'article complet sur PR Newswire Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.prnewswire.com)

Rakuten Medical Presents Long-Term Follow-up Results of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for R/M HNSCC at ESMO 2026

À lire aussi

The Ford Foundation, one of the world’s largest grantmakers, will throw more weight behind democracy

You.com Launches Inference Router, Bringing Enterprise-Grade Reliability to Open-Weight AI Models On Demand

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows

Rakuten Medical Presents Long-Term Follow-up Results of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for R/M HNSCC at ESMO 2026

Partager

À lire aussi

The Ford Foundation, one of the world’s largest grantmakers, will throw more weight behind democracy

You.com Launches Inference Router, Bringing Enterprise-Grade Reliability to Open-Weight AI Models On Demand

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows